{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:15:58Z","timestamp":1788606958378,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The M2 isoform of pyruvate kinase (PKM2) is a key driver of glycolysis in cancer cells and has critical \u2018non-metabolic\u2019 functions in some cancers; however, the role of PKM2 in pancreatic cancer remains unclear. The aim of the current study was to elucidate the role of PKM2 in pancreatic cancer progression and the potential of PKM2 as a therapeutic target. In this study, we observed that PKM2 is highly expressed in patients with pancreatic cancer and is correlated to survival. Elevated PKM2 expression promoted cell proliferation, migration and tumor formation. The inhibition of cell growth by silencing PKM2 is caused by impairment of the autophagy process. To test the potential effects of downregulating PKM2 as a clinical therapy, we constructed an RGD-modified oncolytic adenovirus containing shPKM2 (O<jats:sup>Ad<\/jats:sup>.R.shPKM2) to knock down PKM2 in pancreatic cancer cells. Cells transduced with O<jats:sup>Ad<\/jats:sup>.R.shPKM2 exhibited decreased cell viability, and, in a PANC-1 xenograft model, intratumoral injection of O<jats:sup>Ad<\/jats:sup>.R.shPKM2 resulted in reduced tumor growth. Furthermore, O<jats:sup>Ad<\/jats:sup>.R.shPKM2 induced apoptosis and impaired autophagy in PANC-1 cells. Our results suggested that targeting PKM2 with an oncolytic adenovirus produced a strong antitumor effect, and that this strategy could broaden the therapeutic options for treating pancreatic cancer.<\/jats:p>","DOI":"10.1038\/cddis.2017.230","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T12:43:09Z","timestamp":1496320989000},"page":"e2835-e2835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion"],"prefix":"10.1038","volume":"8","author":[{"given":"Yanni","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongsuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"BFcddis2017230_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913\u20132921.","journal-title":"Cancer Res"},{"key":"BFcddis2017230_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2011.40.1919","volume":"30","author":"NJ Vogelzang","year":"2012","unstructured":"Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 2012; 30: 88\u2013109.","journal-title":"J Clin Oncol"},{"key":"BFcddis2017230_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","journal-title":"Cell"},{"key":"BFcddis2017230_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029\u20131033.","journal-title":"Science"},{"key":"BFcddis2017230_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.molcel.2011.06.003","volume":"42","author":"AN Macintyre","year":"2011","unstructured":"Macintyre AN, Rathmell JC . PKM2 and the tricky balance of growth and energy in cancer. Mol Cell 2011; 42: 713\u2013714.","journal-title":"Mol Cell"},{"key":"BFcddis2017230_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.molcel.2012.01.001","volume":"45","author":"X Gao","year":"2012","unstructured":"Gao X, Wang H, Yang JJ, Liu X, Liu ZR . Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 2012; 45: 598\u2013609.","journal-title":"Mol Cell"},{"key":"BFcddis2017230_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230\u2013233.","journal-title":"Nature"},{"key":"BFcddis2017230_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685\u2013696.","journal-title":"Cell"},{"key":"BFcddis2017230_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cellsig.2014.03.020","volume":"26","author":"P Yang","year":"2014","unstructured":"Yang P, Li Z, Fu R, Wu H, Li Z . Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell Signal 2014; 26: 1853\u20131862.","journal-title":"Cell Signal"},{"key":"BFcddis2017230_CR10","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1038\/onc.2015.6","volume":"34","author":"Q Xu","year":"2015","unstructured":"Xu Q, Liu LZ, Yin Y, He J, Li Q, Qian X et al. Regulatory circuit of PKM2\/NF-kappaB\/miR-148a\/152-modulated tumor angiogenesis and cancer progression. Oncogene 2015; 34: 5482\u20135493.","journal-title":"Oncogene"},{"key":"BFcddis2017230_CR11","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.18632\/oncotarget.3262","volume":"6","author":"W Hu","year":"2015","unstructured":"Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J et al. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget 2015; 6: 6570\u20136583.","journal-title":"Oncotarget"},{"key":"BFcddis2017230_CR12","doi-asserted-by":"publisher","first-page":"e0151635","DOI":"10.1371\/journal.pone.0151635","volume":"11","author":"GH Mohammad","year":"2016","unstructured":"Mohammad GH, Olde Damink SW, Malago M, Dhar DK, Pereira SP . Pyruvate kinase M2 and lactate dehydrogenase A are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS ONE 2016; 11: e0151635.","journal-title":"PLoS ONE"},{"key":"BFcddis2017230_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene 2016; 35: 2031\u20132039.","journal-title":"Oncogene"},{"key":"BFcddis2017230_CR14","doi-asserted-by":"crossref","unstructured":"Lee JS, Oh E, Yoo JY, Choi KS, Yoon MJ, Yun CO. Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells. Oncotarget 2015; 6: 4051\u20134065.","DOI":"10.18632\/oncotarget.3018"},{"key":"BFcddis2017230_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4161\/cbt.9.7.11267","volume":"9","author":"L Ma","year":"2010","unstructured":"Ma L, Liu J, Shen J, Liu L, Wu J, Li W et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 2010; 9: 554\u2013561.","journal-title":"Cancer Biol Ther"},{"key":"BFcddis2017230_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/cgt.2012.40","volume":"19","author":"KJ Zhang","year":"2012","unstructured":"Zhang KJ, Zhang J, Wu YM, Qian J, Liu XJ, Yan LC et al. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Cancer Gene Ther 2012; 19: 619\u2013629.","journal-title":"Cancer Gene Ther"},{"key":"BFcddis2017230_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","volume":"6","author":"CC O\u2019Shea","year":"2004","unstructured":"O\u2019Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611\u2013623.","journal-title":"Cancer Cell"},{"key":"BFcddis2017230_CR18","doi-asserted-by":"publisher","first-page":"e1760","DOI":"10.1038\/cddis.2015.128","volume":"6","author":"Y Yang","year":"2015","unstructured":"Yang Y, Xu H, Shen J, Yang Y, Wu S, Xiao J et al. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells. Cell Death Dis 2015; 6: e1760.","journal-title":"Cell Death Dis"},{"key":"BFcddis2017230_CR19","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","volume":"15","author":"E White","year":"2009","unstructured":"White E, DiPaola RS . The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15: 5308\u20135316.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2017230_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc3262","volume":"12","author":"E White","year":"2012","unstructured":"White E . Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12: 401\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017230_CR21","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-15-0490","volume":"21","author":"E White","year":"2015","unstructured":"White E, Mehnert JM, Chan CS . Autophagy, metabolism, and cancer. Clin Cancer Res 2015; 21: 5037\u20135046.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2017230_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","volume":"524","author":"RM Perera","year":"2015","unstructured":"Perera RM . Transcriptional control of autophagy\u2013lysosome function drives pancreatic cancer metabolism. Nature 2015; 524: 361\u2013365.","journal-title":"Nature"},{"key":"BFcddis2017230_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/15548627.2016.1147670","volume":"12","author":"A Dey","year":"2016","unstructured":"Dey A, Mustafi SB, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R . Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy 2016; 12: 659\u2013670.","journal-title":"Autophagy"},{"key":"BFcddis2017230_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/cdd.2014.143","volume":"22","author":"Y Liu","year":"2015","unstructured":"Liu Y, Levine B . Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ 2015; 22: 367\u2013376.","journal-title":"Cell Death Differ"},{"key":"BFcddis2017230_CR25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.cell.2007.10.035","volume":"131","author":"M Komatsu","year":"2007","unstructured":"Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131: 1149\u20131163.","journal-title":"Cell"},{"key":"BFcddis2017230_CR26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.18632\/oncotarget.2749","volume":"6","author":"WR Liu","year":"2015","unstructured":"Liu WR, Tian MX, Yang LX, Lin YL, Jin L, Ding ZB et al. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget 2015; 6: 846\u2013861.","journal-title":"Oncotarget"},{"key":"BFcddis2017230_CR27","doi-asserted-by":"publisher","first-page":"e27309","DOI":"10.1371\/journal.pone.0027309","volume":"6","author":"XC Peng","year":"2011","unstructured":"Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS ONE 2011; 6: e27309.","journal-title":"PLoS ONE"},{"key":"BFcddis2017230_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/his.12441","volume":"65","author":"C Yuan","year":"2014","unstructured":"Yuan C, Li Z, Wang Y, Qi B, Zhang W, Ye J et al. Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patient prognosis in tongue cancer. Histopathology 2014; 65: 595\u2013605.","journal-title":"Histopathology"},{"key":"BFcddis2017230_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature10598","volume":"480","author":"W Yang","year":"2011","unstructured":"Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011; 480: 118\u2013122.","journal-title":"Nature"},{"issue":"2 Pt A","key":"BFcddis2017230_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2014.01.031","volume":"356","author":"N Wong","year":"2015","unstructured":"Wong N, Ojo D, Yan J, Tang D . PKM2 contributes to cancer metabolism. Cancer Lett 2015; 356 (2 Pt A): 184\u2013191.","journal-title":"Cancer Lett"},{"issue":"Pt 1","key":"BFcddis2017230_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3370001","volume":"337","author":"K Yamada","year":"1999","unstructured":"Yamada K, Noguchi T . Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem J 1999; 337 (Pt 1): 1\u201311.","journal-title":"Biochem J"},{"key":"BFcddis2017230_CR32","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.18632\/oncotarget.6821","volume":"7","author":"R Tang","year":"2016","unstructured":"Tang R, Yang C, Ma X, Wang Y, Luo D, Huang C et al. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget 2016; 7: 5972\u20135984.","journal-title":"Oncotarget"},{"key":"BFcddis2017230_CR33","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.leukres.2015.09.019","volume":"39","author":"Y He","year":"2015","unstructured":"He Y, Wang Y, Liu H, Xu X, He S, Tang J et al. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res 2015; 39: 1428\u20131436.","journal-title":"Leuk Res"},{"key":"BFcddis2017230_CR34","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo W, Hu H, Chang R, Zhong J, Knabel M, O\u2019Meally R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145: 732\u2013744.","journal-title":"Cell"},{"key":"BFcddis2017230_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL . HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51\u201356.","journal-title":"Curr Opin Genet Dev"},{"key":"BFcddis2017230_CR36","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1038\/cddis.2014.297","volume":"5","author":"X Peng","year":"2014","unstructured":"Peng X, Gong F, Chen Y, Jiang Y, Liu J, Yu M et al. Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-alpha-mediated signaling. Cell Death Dis 2014; 5: e1367.","journal-title":"Cell Death Dis"},{"key":"BFcddis2017230_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature11895","volume":"494","author":"MR Warr","year":"2013","unstructured":"Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 2013; 494: 323\u2013327.","journal-title":"Nature"},{"key":"BFcddis2017230_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.4161\/auto.5.7.9252","volume":"5","author":"F Chiacchiera","year":"2009","unstructured":"Chiacchiera F, Simone C . Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism. Autophagy 2009; 5: 1030\u20131033.","journal-title":"Autophagy"},{"key":"BFcddis2017230_CR39","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/onc.2008.23","volume":"27","author":"KK Ho","year":"2008","unstructured":"Ho KK, Myatt SS, Lam EW . Many forks in the path: cycling with FoxO. Oncogene 2008; 27: 2300\u20132311.","journal-title":"Oncogene"},{"key":"BFcddis2017230_CR40","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4161\/cc.9.6.11035","volume":"9","author":"F Chiacchiera","year":"2010","unstructured":"Chiacchiera F, Simone C . The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9: 1091\u20131096.","journal-title":"Cell Cycle"},{"key":"BFcddis2017230_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/mt.2011.242","volume":"20","author":"HH Wong","year":"2012","unstructured":"Wong HH, Jiang G, Gangeswaran R, Wang P, Wang J, Yuan M et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther 2012; 20: 306\u2013316.","journal-title":"Mol Ther"},{"key":"BFcddis2017230_CR42","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ymthe.2004.03.017","volume":"9","author":"TC Liu","year":"2004","unstructured":"Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N et al. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther 2004; 9: 786\u2013803.","journal-title":"Mol Ther"},{"key":"BFcddis2017230_CR43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/mt.2011.159","volume":"20","author":"C Puig-Saus","year":"2012","unstructured":"Puig-Saus C, Gros A, Alemany R, Cascallo M . Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther 2012; 20: 54\u201362.","journal-title":"Mol Ther"},{"key":"BFcddis2017230_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1541-7786.MCR-14-0199","volume":"13","author":"RM Tholey","year":"2015","unstructured":"Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA et al. MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer. Mol Cancer Res 2015; 13: 439\u2013448.","journal-title":"Mol Cancer Res"},{"key":"BFcddis2017230_CR45","unstructured":"Goldenberg MM. New drugs\/drug news. P T 2013; 38: 313\u2013351."},{"key":"BFcddis2017230_CR46","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780\u20132788.","journal-title":"J Clin Oncol"},{"key":"BFcddis2017230_CR47","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol 2016; 34: 2619\u20132626.","journal-title":"J Clin Oncol"},{"key":"BFcddis2017230_CR48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2014.21","volume":"22","author":"KP Kicielinski","year":"2014","unstructured":"Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM . Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22: 1056\u20131062.","journal-title":"Mol Ther"},{"key":"BFcddis2017230_CR49","doi-asserted-by":"publisher","first-page":"e35153","DOI":"10.1371\/journal.pone.0035153","volume":"7","author":"M Ding","year":"2012","unstructured":"Ding M, Cao X, Xu HN, Fan JK, Huang HL, Yang DQ et al. Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS One 2012; 7: e35153.","journal-title":"PLoS One"},{"key":"BFcddis2017230_CR50","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cellsig.2013.11.028","volume":"26","author":"LA Booth","year":"2014","unstructured":"Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P . The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell Signal 2014; 26: 549\u2013555.","journal-title":"Cell Signal"},{"key":"BFcddis2017230_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/onc.2009.519","volume":"29","author":"M Djavaheri-Mergny","year":"2010","unstructured":"Djavaheri-Mergny M, Maiuri MC, Kroemer G . Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717\u20131719.","journal-title":"Oncogene"},{"key":"BFcddis2017230_CR52","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s13238-010-0048-4","volume":"1","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Zhao L, Liu L, Gao P, Tian W, Wang X et al. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell 2010; 1: 468\u2013477.","journal-title":"Protein Cell"},{"key":"BFcddis2017230_CR53","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1038\/cddis.2009.16","volume":"1","author":"E Wirawan","year":"2010","unstructured":"Wirawan E, Vande Walle L, Kersse K, Cornelis S, Claerhout S, Vanoverberghe I et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010; 1: e18.","journal-title":"Cell Death Dis"},{"key":"BFcddis2017230_CR54","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/cdd.2009.33","volume":"16","author":"A Eisenberg-Lerner","year":"2009","unstructured":"Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A . Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966\u2013975.","journal-title":"Cell Death Differ"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2017230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017230","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cddis.2017.230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T18:09:26Z","timestamp":1671732566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2017230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["BFcddis2017230"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2017.230","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]},"assertion":[{"value":"9 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}